NASDAQ: AXSMAxsome Therapeutics Inc Stock
$250.50-1.66 (-0.66%)
Updated Jun 18, 2026
AXSM Price
$250.50
Fair Value Price
N/A
Market Cap
$12.89B
52 Week Low
$96.09
52 Week High
$260.19
P/E
-67.34x
P/B
236.15x
P/S
12.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$708.24M
Earnings
-$188.30M
Gross Margin
92.6%
Operating Margin
-25.91%
Profit Margin
-26.6%
Debt to Equity
12.07
Operating Cash Flow
-$71M
Beta
0.89
Next Earnings
Aug 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AXSM Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AXSM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AXSM
Ranked#105 of 465
Ranked#105 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important AXSM news, forecast changes, insider trades & much more!
AXSM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AXSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AXSM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AXSM is poor value based on its book value relative to its share price (236.15x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
AXSM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AXSM due diligence checks available for Premium users.
Valuation
AXSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-67.34x
Industry
15.77x
Market
9.47x
AXSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
236.15x
Industry
4.95x
AXSM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AXSM's financial health
Profit margin
Revenue
$191.2M
Net Income
-$64.5M
Profit Margin
-33.8%
AXSM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AXSM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$713.6M
Liabilities
$659.0M
Debt to equity
12.07
AXSM's short-term assets ($611.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AXSM's short-term assets ($611.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AXSM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AXSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.7M
Investing
-$121.0k
Financing
$3.0M
AXSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AXSM vs Biotech Stocks
Axsome Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.